Receptors for acylethanolamides-GPR55 and GPR119

Prostaglandins and Other Lipid Mediators

Volumn 89, Issue 3-4, 2009, Pages 105-111

  Godlewski, Grzegorz ^a   Offertáler, László ^a   Wagner, Jens A ^a   Kunos, George ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Cannabinoid; G protein coupled receptor; Lipid ligand

Indexed keywords

ACYLETHANOLAMIDE DERIVATIVE; AMIDE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CARRIER PROTEIN; G PROTEIN COUPLED RECEOTIR 119; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; N ACYLPHOSPHATIDYLETHANOLAMINE; N OLEOYLETHANOLAMINE; PALMIDROL; TRANSIENT RECEPTOR POTENTIAL VANILLOID 1 RECEPTOR; UNCLASSIFIED DRUG;

HUMAN; NOCICEPTION; NONHUMAN; OBESITY; PHOSPHOLIPID MEMBRANE; PROTEIN STRUCTURE; REVIEW; TISSUE DISTRIBUTION;

AMIDES; ANIMALS; CANNABINOIDS; ENDOCANNABINOIDS; ENDOTHELIUM; FATTY ACIDS; LIGANDS; LYSOPHOSPHOLIPIDS; ORGAN SPECIFICITY; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 69549130581     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2009.07.001     Document Type: Review

References (75)

1. Borrelli F., and Izzo A.A. Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. Best Pract Res Clin Endocrinol Metab 23 1 (2009) 33-49
2. Di Marzo V., Fontana A., Cadas H., et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372 6507 (1994) 686-691
3. Liu J., Wang L., Harvey-White J., et al. A biosynthetic pathway for anandamide. Proc Natl Acad Sci USA 103 36 (2006) 13345-13350
4. Simon G.M., and Cravatt B.F. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem 283 14 (2008) 9341-9349
5. Gillum M.P., Zhang D., Zhang X.M., et al. N-acylphosphatidylethanolamine, a gut-derived circulating factor induced by fat ingestion, inhibits food intake. Cell 135 5 (2008) 813-824
6. Devane W.A., Hanus L., Breuer A., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 5090 (1992) 1946-1949
7. Mechoulam R., Ben-Shabat S., Hanus L., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50 1 (1995) 83-90
8. Sugiura T., Kondo S., Sukagawa A., et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215 1 (1995) 89-97
9. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 6284 (1990) 561-564
10. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 6441 (1993) 61-65
11. Zygmunt P.M., Petersson J., Andersson D.A., et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 6743 (1999) 452-457
12. Begg M., Pacher P., Batkai S., et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 106 2 (2005) 133-145
13. Ross R.A. The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 30 3 (2009) 156-163
14. Brown A.J. Novel cannabinoid receptors. Br J Pharmacol 152 5 (2007) 567-575
15. Hiley C.R., and Kaup S.S. GPR55 and the vascular receptors for cannabinoids. Br J Pharmacol 152 5 (2007) 559-561
16. Petitet F., Donlan M., and Michel A. GPR55 as a new cannabinoid receptor: still a long way to prove it. Chem Biol Drug Des 67 3 (2006) 252-253
17. Baker D., Pryce G., Davies W.L., and Hiley C.R. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27 1 (2006) 1-4
18. Fu J., Gaetani S., Oveisi F., et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425 6953 (2003) 90-93
19. Cluny N.L., Keenan C.M., Lutz B., Piomelli D., and Sharkey K.A. The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice. Neurogastroenterol Motil (2008)
20. Overton H.A., Babbs A.J., Doel S.M., et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 3 3 (2006) 167-175
21. Lambert D.M., Vandevoorde S., Jonsson K.O., and Fowler C.J. The palmitoylethanolamide family: a new class of anti-inflammatory agents?. Curr Med Chem 9 6 (2002) 663-674
22. Lo Verme J., Fu J., Astarita G., et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67 1 (2005) 15-19
23. Griffin G., Tao Q., and Abood M.E. Cloning and pharmacological characterization of the rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther 292 3 (2000) 886-894
24. Ryberg E., Larsson N., Sjogren S., et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152 7 (2007) 1092-1101
25. Oh D.Y., Kim K., Kwon H.B., and Seong J.Y. Cellular and molecular biology of orphan G protein-coupled receptors. Int Rev Cytol 252 (2006) 163-218
26. Fredriksson R., Hoglund P.J., Gloriam D.E., Lagerstrom M.C., and Schioth H.B. Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives. FEBS Lett 554 3 (2003) 381-388
27. Sawzdargo M., Nguyen T., Lee D.K., et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 64 2 (1999) 193-198
28. Waldeck-Weiermair M., Zoratti C., Osibow K., et al. Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci 121 Pt 10 (2008) 1704-1717
29. Lauckner J.E., Jensen J.B., Chen H.Y., Lu H.C., Hille B., and Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 105 7 (2008) 2699-2704
30. Oka S., Nakajima K., Yamashita A., Kishimoto S., and Sugiura T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 362 4 (2007) 928-934
31. Johns D.G., Behm D.J., Walker D.J., et al. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152 5 (2007) 825-831
32. Jarai Z., Wagner J.A., Varga K., et al. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96 24 (1999) 14136-14141
33. Offertaler L., Mo F.M., Batkai S., et al. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63 3 (2003) 699-705
34. Henstridge C.M., Balenga N.A., Ford L.A., Ross R.A., Waldhoer M., and Irving A.J. The GPR55 ligand l-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 23 1 (2009) 183-193
35. Oka S., Toshida T., Maruyama K., Nakajima K., Yamashita A., and Sugiura T. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J Biochem 145 1 (2009) 13-20
36. Yin H., Chu A., Li W., et al. Lipid G-protein-coupled receptor ligand identification using beta-arrestin pathhunter assay. J Biol Chem (2009)
37. Corda D., Iurisci C., and Berrie C.P. Biological activities and metabolism of the lysophosphoinositides and glycerophosphoinositols. Biochim Biophys Acta 1582 1-3 (2002) 52-69
38. Busse R., Edwards G., Feletou M., Fleming I., Vanhoutte P.M., and Weston A.H. EDHF: bringing the concepts together. Trends Pharmacol Sci 23 8 (2002) 374-380
39. Pisanti S., Borselli C., Oliviero O., Laezza C., Gazzerro P., and Bifulco M. Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. J Cell Physiol 211 2 (2007) 495-503
40. Mo F.M., Offertaler L., and Kunos G. Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur J Pharmacol 489 1-2 (2004) 21-27
41. Mukhopadhyay S., Chapnick B.M., and Howlett A.C. Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol Heart Circ Physiol 282 6 (2002) H2046-H2054
42. Randall M.D., Kendall D.A., and O'Sullivan S. The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142 1 (2004) 20-26
43. Ho W.S., and Hiley C.R. Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. Br J Pharmacol 138 7 (2003) 1320-1332
44. Wagner J.A., Varga K., Jarai Z., and Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33 1 Pt 2 (1999) 429-434
45. Walter L., Franklin A., Witting A., et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 23 4 (2003) 1398-1405
46. Kreutz S., Koch M., Bottger C., Ghadban C., Korf H.W., and Dehghani F. 2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells. Glia 57 3 (2009) 286-294
47. McHugh D., Tanner C., Mechoulam R., Pertwee R.G., and Ross R.A. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Mol Pharmacol 73 2 (2008) 441-450
48. Zhang X., Wang J.F., Kunos G., and Groopman J.E. Cannabinoid modulation of Kaposi's sarcoma-associated herpesvirus infection and transformation. Cancer Res 67 15 (2007) 7230-7237
49. Ford W.R., Honan S.A., White R., and Hiley C.R. Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol 135 5 (2002) 1191-1198
50. White R., and Hiley C.R. The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery. Br J Pharmacol 125 3 (1998) 533-541
51. White R., and Hiley C.R. A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br J Pharmacol 122 8 (1997) 1573-1584
52. Su J.Y., and Vo A.C. 2-Arachidonylglyceryl ether and abnormal cannabidiol-induced vascular smooth muscle relaxation in rabbit pulmonary arteries via receptor-pertussis toxin sensitive G proteins-ERK1/2 signaling. Eur J Pharmacol 559 2-3 (2007) 189-195
53. Kozlowska H., Baranowska M., Schlicker E., Kozlowski M., Laudanski J., and Malinowska B. Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary artery. J Hypertens 25 11 (2007) 2240-2248
54. Mackie K. Cannabinoid receptor homo- and heterodimerization. Life Sci 77 14 (2005) 1667-1673
55. Ledent C., Valverde O., Cossu G., et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283 5400 (1999) 401-404
56. Godlewski G., Offertaler L., Osei-Hyiaman D., et al. The endogenous brain constituent N-arachidonoyl l-serine is an activator of large conductance Ca2+-activated K+ channels. J Pharmacol Exp Ther 328 1 (2009) 351-361
57. Milman G., Maor Y., Abu-Lafi S., et al. N-arachidonoyl l-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci USA 103 7 (2006) 2428-2433
58. Staton P.C., Hatcher J.P., Walker D.J., et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139 1 (2008) 225-236
59. Takeda S., Kadowaki S., Haga T., Takaesu H., and Mitaku S. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett 520 1-3 (2002) 97-101
60. Overton H.A., Fyfe M.C., and Reynet C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol 153 Suppl. 1 (2008) S76-81
61. Soga T., Ohishi T., Matsui T., et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 326 4 (2005) 744-751
62. Chu Z.L., Jones R.M., He H., et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 148 6 (2007) 2601-2609
63. Lauffer L.M., Iakoubov R., and Brubaker P.L. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58 5 (2009) 1058-1066
64. Lan H., Vassileva G., Corona A., et al. GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. J Endocrinol 201 2 (2009) 219-230
65. Sakamoto Y., Inoue H., Kawakami S., et al. Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells. Biochem Biophys Res Commun 351 2 (2006) 474-480
66. Ning Y., O'Neill K., Lan H., et al. Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells. Br J Pharmacol 155 7 (2008) 1056-1065
67. Reimann F., Habib A.M., Tolhurst G., Parker H.E., Rogers G.J., and Gribble F.M. Glucose sensing in L cells: a primary cell study. Cell Metab 8 6 (2008) 532-539
68. Semple G., Fioravanti B., Pereira G., et al. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J Med Chem 51 17 (2008) 5172-5175
69. Chu Z.L., Carroll C., Alfonso J., et al. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 149 5 (2008) 2038-2047
70. Schwartz G.J., Fu J., Astarita G., et al. The lipid messenger OEA links dietary fat intake to satiety. Cell Metab 8 4 (2008) 281-288
71. Fu J., Kim J., Oveisi F., Astarita G., and Piomelli D. Targeted enhancement of oleoylethanolamide production in proximal small intestine induces across-meal satiety in rats. Am J Physiol Regul Integr Comp Physiol 295 1 (2008) R45-50
72. Guzman M., Lo Verme J., Fu J., Oveisi F., Blazquez C., and Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem 279 27 (2004) 27849-27854
73. Sun Y., Alexander S.P., Garle M.J., et al. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol 152 5 (2007) 734-743
74. Galan-Rodriguez B., Suarez J., Gonzalez-Aparicio R., et al. Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons. Neuropharmacology 56 3 (2009) 653-664
75. Suardiaz M., Estivill-Torrus G., Goicoechea C., Bilbao A., and Rodriguez de Fonseca F. Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. Pain 133 1-3 (2007) 99-110